lazabemide,
Ro 19-6327,
Ro-19-6327,
Lazabemide,
103878-84-8,
Ro-19-6327,
N-(2-Aminoethyl)-5-chloropicolinamide,
CCRIS 7301,
UNII-420HD787N9,
N-(2-aminoethyl)-5-chloropyridine-2-carboxamide,
Ro 19-6327 hydrate,
CHEMBL279390,
Ro 19-6327/000,
420HD787N9,
C8H10ClN3O,
2-Pyridinecarboxamide, N-(2-aminoethyl)-5-chloro-,
N-(2-Aminoethyl)-5-chloro-2-pyridinecarboxamide hydrate,
N-(2-Aminoethyl)-5-chloro-2-pyridinecarboxamide;N-(2-Aminoethyl)-5-chloro-2-pyridinecarboxamide,
NCGC00167737-01,
Lazabemide [USAN:INN],
Lazabemide [USAN:INN:BAN],
n-(2-aminoethyl)-5-chloro-2-pyridinecarboxamide,
AC1L2FXN,
AC1Q3PNP,
Lazabemide (USAN/INN),
SCHEMBL121998,
GTPL6640,
DTXSID2048294,
JZXRLKWWVNUZRB-UHFFFAOYSA-N,
ZINC1542229,
BDBM50029816,
MFCD20488051,
AKOS006272560,
CS-4008,
MCULE-7045156412,
Ro-196327,
AC-27411,
HY-14201,
LS-171892,
Ro-196327000,
FT-0631029,
D04681,
2-Pyridinecarboxamide,N-(2-aminoethyl)-5-chloro-,
N-(2-aminoethyl)-5-chloro-2-pyridine carboxamide,
BRD-K51486818-002-01-2,
5-Chloro-pyridine-2-carboxylic acid (2-amino-ethyl)-amide,
Lazabemine,
Tempium,
Pakio,
Lazabemide hydrate,
LAZEBEMIDE,
D06QRW,
D08QMF,
Ro 19-6327,
C8-H10-Cl-N3-O,
CID71307,
AR-1J7635,
N-(2-aminoethyl)-5-chloropicolin-amide,
Ro-41-3776,
Ro-19-6327/000,
C059303,
104576-59-2,